8-K: Amended loan schedule lifts secured debt to $11,094,279 through August 2026

Acura Pharmaceuticals, Inc. filed an amended loan schedule to its November 10, 2022 secured promissory note with Abuse Deterrent Pharma, LLC. The schedule adds Loans #1 through #64, increasing the aggregated principal from the original $2,319,279 to $11,094,279. New loans include $7,075,000 across Loans #1 through #50 dated December 22, 2022 through December 31, 2025, plus additional advances of $100,000 or $200,000 each through August 14, 2026. The amendment was signed by Senior Vice President and CFO Robert A. Seiser on August 20, 2026.

Acura Pharmaceuticals, Inc. filed an amended loan schedule to its November 10, 2022 secured promissory note with Abuse Deterrent Pharma, LLC. The schedule adds Loans #1 through #64, increasing the agg